Connect Biopharma Holdings (CNTB) risk factors, FY2025 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We might never generate any additional revenue or become profitable or, if we achieve profitability, we might be unable to sustain it68% rewritten
2. 02to fund our Product Candidate through regulatory approvals, and we will need additional capital to complete their development and commercializationNew
3. 03Raising additional capital may cause substantial dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or Product Candidates45% rewritten
4. 04Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

1. 05Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unforeseen costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our Product Candidates
2. 06We depend on enrollment of patients in our clinical trials for our Product Candidates. If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected60% rewritten
3. 07will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a studyNew
4. 08Our Product Candidates may be associated with serious adverse events or undesirable side effects or have other properties that could delay or halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences
5. 09We have conducted and may continue to conduct clinical trials for our Product Candidates in international sites, and the applicable regulatory authority may not accept data from trials conducted in foreign locations
6. 10Interim, “top-line” or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data75% rewritten
7. 11Further, there have been regulatory initiatives in the PRC in the past few years in relation to clinical trial approvals, the evaluation and approval of some drugs and medical devices and the simplification and acceleration of the clinical trial process
8. 12We have only one Product Candidate, rademikibart, currently in clinical development. If we are unable to successfully develop our Product Candidates or experience significant delays in doing so, our business will be materially harmed
9. 13Although our management team has experience doing so, as a Company we have never submitted an NDA or BLA, and may be unable to do so for any of our Product Candidates
10. 14The regulatory approval processes of the FDA, the NMPA and comparable foreign authorities are lengthy, time consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for our Product Candidates, our business will be substantially harmed78% rewritten
11. 15or any future Product Candidates, which would significantly harm our business, financial condition, results of operations and prospectsNew
12. 16Our Product Candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
13. 17The proposed revision of the EU legislation on pharmaceuticals could lead to uncertainties over the regulatory framework that will be applicable to medicinal products in the EU 80% rewritten

Risks Related to Our Reliance on Third Parties

1. 18Our current and anticipated future dependence upon others for the manufacture of our Product Candidates or drugs may adversely affect our future profit margins and our ability to commercialize any Product Candidates that receive marketing approval on a timely and competitive basis
2. 19Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed
3. 20We have entered into and expect to seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and we may not realize the benefits of such relationships
4. 21Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction
5. 22If the custodians or authorized users of our controlling non-tangible assets, including chops and seals, fail to fulfill their responsibilities, or misappropriate or misuse these assets, our business and operations may be materially and adversely affected

Risks Related to Commercialization of Our Product Candidates

1. 23Even if our Product Candidates receive regulatory approval, they will be subject to ongoing regulatory review and significant post-marketing regulatory requirements and oversight
2. 24The occurrence of any event or penalty described above may inhibit our ability to commercialize our Product Candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
3. 25The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability
4. 26The commercial success of our Product Candidates will depend upon the degree of market acceptance of such Product Candidates by physicians, patients, healthcare payors and others in the medical community24% rewritten
5. 27instance. It is possible that a third-party payor may consider our products as substitutable and only offer to provide coverage for a less expensive productNew
6. 28We face significant competition, and if our competitors develop technologies or Product Candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected
7. 29We expect to face competition from existing products and products in development for each of our Product Candidates as described in the section titled “Business—Competition” elsewhere in this Annual Report on Form 10-K
8. 30If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer
9. 31Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

Risks Related to Our Business Operations and Industry

1. 32The increasing use of AI and machine learning in drug discovery and development introduces new and evolving risks that could harm our business and competitive positionNew
2. 33Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
3. 34We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
4. 35We may encounter difficulties in managing our growth and expanding our operations successfully
5. 36We have incurred and may continue to incur significant costs for our clinical trials for our Product Candidates43% rewritten
6. 37regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputationNew
7. 38We are subject to various foreign, federal, and state healthcare laws and regulations, and failure to comply with these laws and regulations could harm our results of operations and financial condition
8. 39Because of the breadth of these laws and the limited statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws
9. 40Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition89% rewritten
10. 41penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAANew
11. 42As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional, similar laws and regulations that may affect how we conduct business
12. 43Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our Product Candidates and may affect the prices we may set25% rewritten
13. 44Some of our investments may be subject to review from the Committee on Foreign Investment in the U.S. (“CFIUS”) which may delay or block a transaction from closing
14. 45If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products37% rewritten
15. 46Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
16. 47We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management

Risks Related to Intellectual Property

1. 48Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our proprietary technologies
2. 49If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors and other third parties from commercializing Product Candidates similar or identical to ours would be adversely affected
3. 50commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture, have manufactured, or commercialize products without infringing third-party patent rightsNew
4. 51The patent protection and patent prosecution for our current or any future Product Candidates may be dependent on third parties53% rewritten
5. 52NMPA or FDA could increase the risk of early generic competition with our products in the PRC, the U.S., or other territoriesNew
6. 53Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
7. 54Third-party claims or litigation alleging infringement, misappropriation or other violation of, or seeking to invalidate, patents or other intellectual and proprietary rights, may delay or prevent the development and commercialization of any of our current or future Product Candidates
8. 55We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our Product Candidates
9. 56We may need to acquire or license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
10. 57We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful
11. 58Derivation, interference or other proceedings may be necessary to determine priority of inventions relating to our current or future Product Candidates, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
12. 59Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
13. 60Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our current and future patent applications or those of our future licensors and the enforcement or defense of our current and future issued patents or those of our future licensors
14. 61Changes in U.S. patent law, PRC patent law or patent laws in other countries could diminish the value of patents in general, thereby impairing our ability to protect our current and any future Product Candidates
15. 62We may not be able to protect our intellectual property rights throughout the world, including in the U.S., Europe and the PRC
16. 63Compulsory standards for remuneration to creators or inventors of the patents they contribute to our business could be considerable
17. 64If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
18. 65We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
19. 66If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected44% rewritten
20. 67The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators and partners
21. 68Intellectual property rights do not necessarily address all potential threats

Risks Related to Ownership of Our Ordinary Shares

1. 69The trading price of our ordinary shares could be highly volatile, and purchasers of our ordinary shares could incur substantial losses
2. 70Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations and the price of our ordinary shares
3. 71If we fail to meet the continued listing requirements of Nasdaq, it could result in a delisting of our ordinary shares38% rewritten
4. 72An active, liquid trading market for our ordinary shares may not be maintained21% rewritten
5. 73Our executive officers, directors and principal shareholders, if they choose to act together, will have the ability to control or significantly influence all matters submitted to shareholders for approval25% rewritten
6. 74We do not currently intend to pay dividends on our securities, and, consequently, the ability to achieve a return on investment in our ordinary shares will depend on appreciation, if any, in the price of our ordinary shares28% rewritten
7. 75We are an emerging growth company and smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our ordinary shares less attractive to investors
8. 76As a result, we do not know if some investors will find our ordinary shares less attractive. The result may be a less active trading market for our ordinary shares, and the price of our ordinary shares may become more volatile74% rewritten
9. 77completed fiscal year and our voting and non-voting ordinary shares held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarterNew
10. 78Under our amended and restated memorandum and articles of association, investors do not have the same rights with respect to shareholder meetings and voting that shareholders of some U.S. corporations have
11. 79We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses
12. 80Fluctuations in currency exchange rates may have a material adverse effect on our results of operations and the value of any investment in our ordinary shares
13. 81Investors’ right to participate in any future rights offerings may be limited, which may cause dilution to holdings in our ordinary shares52% rewritten
14. 82Investors may face difficulties in protecting their interests, and the ability to protect the rights of investors through U.S. courts may be limited, because we are incorporated under Cayman Islands law
15. 83As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management or members of our Board than they would as public shareholders of a company incorporated in the U.S
16. 84Our amended and restated memorandum and articles of association contain anti-takeover provisions that could discourage a third party from acquiring us, which could limit our shareholders’ opportunity to sell their shares, including ordinary shares represented by our ordinary shares, at a premium
17. 85We could be subject to securities class action litigation or shareholder activism40% rewritten
18. 86If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, the market price for our ordinary shares and trading volume could decline32% rewritten
19. 87The increasing use of social media platforms presents new risks and challenges

Risks Related to Doing Business in the PRC

1. 88Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies
2. 89The PRC government may intervene in or influence our operations in accordance with laws and regulations, which could result in a material change in our operations and significantly and adversely impact the value of our ordinary shares
3. 90Compliance with the PRC’s Data Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant expenses and could materially affect our business
4. 91The approval of and the filing with the CSRC has been, and may in the future, be required under a PRC regulation in connection with any future offerings of our securities in the U.S. market
5. 92Additionally, the requirements imposed by the New Filing Rules may delay or deter future offerings of our securities and impair our ability to obtain financing on acceptable terms or at all
6. 93As a holding company, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries to make dividend paymentsNew
7. 94PRC regulation of loans to, and direct investments in, PRC entities by offshore holding companies may restrict or prevent us from making loans or additional capital contributions to our PRC subsidiaries
8. 95Any failure to comply with PRC regulations regarding the registration requirements for employee share incentive plans may subject our equity incentive plan participants or us to fines and other legal or administrative sanctions
9. 96PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries’ ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws
10. 97We may be treated as a resident enterprise for PRC tax purposes under the PRC Enterprise Income Tax Law, and we may therefore be subject to PRC income tax on our global income
11. 98Dividends paid to our non-PRC investors (should we ever pay dividends) and gains on the sale of our ordinary shares by our non-PRC investors may become subject to PRC tax
12. 99We and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or immovable properties located in the PRC owned by non-PRC companies
13. 100We and our shareholders face uncertainties with respect to reorganizations or restructurings that we may undertake
14. 101We could be adversely affected by rising political tensions and any potential conflicts between the U.S. and the PRC
15. 102Recent litigation, regulatory scrutiny and negative publicity surrounding PRC-based companies listed in the U.S. may result in increased regulatory scrutiny of us and negatively impact the trading price of our ordinary shares
16. 103The enforcement of the PRC Labor Law, Labor Contract Law, and other labor-related regulations in the PRC may increase our labor costs and limit our flexibility to use labor. If we fail to comply with PRC labor-related laws, we may be exposed to penalties
17. 104Our business benefits from tax benefits or financial incentives and discretionary policies granted by governmental authorities in the PRC. Expiration, elimination or reduction of these incentives or policies would have an adverse effect on our results of operations
18. 105The pharmaceutical industry in the PRC is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs
19. 106We may be restricted by industry-specific laws and regulations from transferring our scientific data outside of the PRC

General Risks

1. 107Inflationary pressures and persistently high prices and uncertain availability of raw materials or other inputs used by our suppliers, or instability in logistics and related costs, could negatively impact our operation, preclinical studies and clinical trials27% rewritten
2. 108We or the third parties upon whom we depend may be adversely affected by earthquakes, fires, floods or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster26% rewritten
3. 109If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
4. 110We may incur costs and expenses due to injuries to our employees resulting from the use of hazardous materials. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous materials